Engineering probiotics to inhibit Clostridioides difficile infection by dynamic regulation of intestinal metabolism

Abstract

Clostridioides difficile infection (CDI) results in significant morbidity and mortality in hospitalised patients. The pathogenesis of CDI is intrinsically related to the ability of C. difficile to shuffle between active vegetative cells and dormant endospores through the processes of germination and sporulation. Here, we hypothesise that dysregulation of microbiome-mediated bile salt metabolism contributes to CDI and that its alleviation can limit the pathogenesis of CDI. We engineer a genetic circuit harbouring a genetically encoded sensor, amplifier and actuator in probiotics to restore intestinal bile salt metabolism in response to antibiotic-induced microbiome dysbiosis. We demonstrate that the engineered probiotics limited the germination of endospores and the growth of vegetative cells of C. difficile in vitro and further significantly reduced CDI in model mice, as evidenced by a 100% survival rate and improved clinical outcomes. Our work presents an antimicrobial strategy that harnesses the host-pathogen microenvironment as the intervention target to limit the pathogenesis of infection.

Abstract of "Engineering probiotics to inhibit Clostridioides difficile infection by dynamic regulation of intestinal metabolism" by Koh E, Hwang IY, Lee HL et al., https://doi.org/10.1038/s41467-022-31334-z, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.